Detecting functional changes with [18F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy

Psychonomic Bulletin and Review

Volumn 4, Issue 1, 1997, Pages

  Chapman, David W ^a,b   Jans, Hans Sonke ^a   Ma, Ivy ^b   Mercer, John R ^a   Wiebe, Leonard I ^a   Wuest, Melinda ^a   Moore, Ronald B ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Renal cell carcinoma; Sunitinib; Tyrosine kinase inhibitor; 18F FAZA

Indexed keywords

EID: 84930789402     PISSN: 10699384     EISSN: 15315320     Source Type: Journal    
DOI: 10.1186/s13550-014-0027-5     Document Type: Article

References (53)

1. Linehan WM, Walter MM, Zbar B: The genetic base of cancer of the kidney.J Urol 2003, 170:163–172.
2. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H: Renal tumors: diagnostic and prognostic biomarkers.Am J Surg Pathol 2013, 37:1518–1531.
3. American Cancer Society: Cancer Facts and Figures. Atlanta ACS: American Cancer Society; 2013. http://www.cancer.org/Research/CancerFactsFigures/index. Accessed January 2014.
4. Cohen HT, McGovern FJ: Renal-cell carcinoma.N Engl J Med 2005, 353:2477–2490.
5. Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders PFA, Staehler M, Volpe A: Guidelines on Renal Cell Carcinoma. Arnhem: European Association of Urology (EAU); 2013. http://www.uroweb.org/gls/pdf/10_Renal_Cell_Carcinoma_LR.pdf. Accessed January 2014.
6. Basu B, Eisen T: Perspectives in drug development for metastatic renal cell cancer.Target Oncol 2010, 5:139–156.
7. Dutcher JP: Recent developments in the treatment of renal cell carcinoma.Ther Adv Urol 2013, 5:338–353.
8. Schrader AJ, Hofmann R: Metastatic renal cell carcinoma: recent advances and current therapeutic options.Anticancer Drugs 2008, 19:235–245.
9. Gross-Goupil M, Massard C, Ravaud A: Targeted therapies in metastatic renal cell carcinoma: overview of the past year.Curr Urol Rep 2012, 13:16–23.
10. Zhang J, Yang PL, Gray NS: Targeting cancer with small molecule kinase inhibitors.Nat Rev Cancer 2009, 9:28–39.
11. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.Clin Cancer Res 2003, 9:327–337.
12. Adams VR, Leggas M: Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.Clin Ther 2007, 29:1338–1353.
13. Petrelli A, Giordano S: From single- to mutli-target drugs in cancer therapy: when aspecificity becomes an advantage.Curr Med Chem 2008, 15:422–432.
14. Wood L: Sunitinib malate for the treatment of renal cell carcinoma.Expert Opin Pharmacother 2012, 13:1323–1336.
15. Escudier B, Albiges L, Sonpavde G: Optimal management of metastatic renal cell carcinoma: current status.Drugs 2013, 73:427–438.
16. Castellano D, Ravaud A, Schmidinger M, De Velasco G, Vazquez F: Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers.Cancer Treat Rev 2013, 39:230–240.
17. Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV: Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.Oncogene 2010, 29:2938–2949.
18. Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ, Rodríguez-Enríquez S, Moreno-Sánchez R: HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms.Mini Rev Med Chem 2009, 9:1084–1101.
19. Cassavaugh J, Lounsbury KM: Hypoxia-mediated biological control.J Cell Biochem 2011, 112:735–744.
20. Chapman JD, Schneider RF, Urbain JL, Hanks GE: Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation.Semin Radiat Oncol 2001, 11:47–57.
21. Krohn KA, Link JM, Mason RP: Molecular imaging of hypoxia.J Nucl Med 2008, 49(Suppl 2):129S–148S.
22. Sacco E, Pinto F, Totaro A, D'Addessi A, Racioppi M, Gulino G, Volpe A, Marangi F, D'Agostino D, Bassi P: Imaging of renal cell carcinoma: state of the art and recent advances.Urol Int 2011, 86:125–139.
23. Krajewski KM, Giardino AA, Zukotynski K, Van den Abbeele AD, Pedrosa I: Imaging in renal cell carcinoma.Hematol Oncol Clin North Am 2011, 25:687–715.
24. Carlin S, Humm JL: PET of hypoxia: current and future perspectives.J Nucl Med 2012, 53:1171–1174.
25. Wuest M, Wuest F: Positron emission tomography radiotracers for imaging hypoxia.J Labelled Comp Radiopharm 2013, 56:244–250.
26. 18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors.Nucl Med Biol 2003, 30:317–326.
27. 18F-fluoroazomycin arabinoside.J Nucl Med 2005, 46:106–113.
28. 18F]FAZA–first small animal PET results.J Pharm Pharm Sci 2007, 10:203–211.
29. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ: Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model.J Nucl Med 1999, 40:177–183.
30. Dunphy MP, Lewis JS: Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.J Nucl Med 2009, Suppl 1:106S–121S.
31. Valable S, Petit E, Roussel S, Marteau L, Toutain J, Divoux D, Sobrio F, Delamare J, Barré L, Bernaudin M: Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.Nucl Med Biol 2011, 38:781–793.
32. 18F-fluoromisonidazole PET/CT study.J Nucl Med 2011, 52:1048–1055.
33. 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.Int J Oncol 2012, 41:1593–1600.
34. Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fosså SD, Lilleby W: Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.Clin Oncol (R Coll Radiol) 2011, 23:339–343.
35. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.Cancer Biother Radiopharm 2009, 24:137–144.
36. Lyrdal D, Boijsen M, Suurküla M, Lundstam S, Stierner U: Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.Nucl Med Commun 2009, 30:519–524.
37. Solomon B, Binns D, Roselt P, Weibe LI, McArthur GA, Cullinane C, Hicks RJ: Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging.Mol Cancer Ther 2005, 4:1417–1422.
38. Liu G, Jeraj R, Vanderhoek M, Perlman S, Kolesar J, Harrison M, Simoncic U, Eickhoff J, Carmichael L, Chao B, Marnocha R, Ivy P, Wilding G: Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.Clin Cancer Res 2011, 15(17):7634–7644.
39. Bruce JY, Kolesar JM, Hammers H, Stein MN, Carmichael L, Eickhoff J, Johnston SA, Binger KA, Heideman JL, Perlman SB, Jeraj R, Liu G: A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. Cancer Chemother Pharmacol 2014. doi:10.1007/s00280-013-2373-9.
40. 18F]FAZA: reaction parameters and automation.Appl Radiat Isot 2005, 62:897–901.
41. Verwer EE, van Velden FHP, Bahce I, Yaqub M, Schuit RC, Windhorst AD, Raijmakers P, Lammertsma AA, Smit EF, Boellaard R: Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients.Eur J Nucl Med Mol Imaging 2013, 40:1523–1531.
42. 14C-misonidazole to hypoxic cells: kinetic dependence on oxygen concentration and misonidazole concentration.Int J Radiat Oncol Biol Phys 1984, 10:1327–1331.
43. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ: Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic metaanalysis.Cancer Chemother Pharmacol 2010, 66:357–371.
44. 18F]FAZA).Radiat Oncol 2011, 6:165–175.
45. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.J Clin Oncol 2006, 24:2098–2104.
46. Dorow DS, Cullinane C, Conus N, Roselt P, Binns D, McCarthy TJ, McArthur GA, Hicks RJ: Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033.Eur J Nucl Med Mol Imaging 2006, 33:441–452.
47. Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, Mekhail TM, Olencki TE, Elson P, Bukowski RM: F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.J Clin Oncol 2003, 21:3995–4000.
48. Dilhuydy MS, Durieux A, Pariente A, de Clermont H, Pasticier G, Monteil J, Ravaud A: PET scans for decision-making in metastatic renal cell carcinoma: a single-institution evaluation.Oncology 2006, 70:339–344.
49. Arabi M, Piert M: Hypoxia PET/CT imaging: implications for radiation oncology.Q J Nucl Med Mol Imaging 2010, 54:500–509.
50. Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Jonasch E: Clinical outcomes in patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol: Tannir NM 2013. doi:10.1016/j.juro.2013.08.090.
51. Murakami M, Zhao S, Zhao Y, Yu W, Fatema CN, Nishijima KI, Yamasaki M, Takiguchi M, Tamaki N, Kuge Y: Increased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft model.Oncol Lett 2013, 6:667–672.
52. Gaustad JV, Simonsen TG, Leinaas MN, Rofstad EK: Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts.BMC Cancer 2012, 12:388–403.
53. Gaustad JV, Simonsen TG, Roa AM, Rofstad EK: Tumors exposed to acute cyclic hypoxia show increased vessel density and delayed blood supply.Microvasc Res 2013, 85:10–15.